Skip Navigation



European Heart Journal Advance Access published online on April 8, 2005
European Heart Journal, doi:10.1093/eurheartj/ehi253
This Article
Right arrow Full Text (Rapid PDF)
Right arrow All Versions of this Article:
26/13/1314    most recent
ehi253v2
ehi253v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Geluk, C. A.
Right arrow Articles by van Gilst, W. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Geluk, C. A.
Right arrow Articles by van Gilst, W. H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

European Heart Journal © The European Society of Cardiology 2005; all rights reserved
Received October 19, 2004
Revised February 25, 2005
Accepted March 3, 2005

Clinical research

Impact of statins in microalbuminuric subjects with the metabolic syndrome: a substudy of the PREVEND Intervention Trial

Christiane A. Geluk 1*, Folkert W. Asselbergs 1, Hans L. Hillege 1, Stephan J.L. Bakker 2, Paul E. de Jong 3, Felix Zijlstra 1, and Wiek H. van Gilst 4

1 Department of Cardiology, Thoraxcenter, University Medical Center Groningen, University of Groningen, Postbus 30001, Hanzeplein 1, 9700 RB, Groningen, The Netherlands
2 Department of Internal Medicine, University Medical Center Groningen, University of Groningen, The Netherlands
3 Department of Internal Medicine, Division of Nephrology, University Medical Center Groningen, University of Groningen, The Netherlands
4 Department of Cardiology, Thoraxcenter, University Medical Center Groningen, University of Groningen, Postbus 30001, Hanzeplein 1, 9700 RB, Groningen, The Netherlands; Department of Clinical Pharmacology, University Medical Center Groningen, University of Groningen, The Netherlands


  Abstract

Aims Microalbuminuria frequently clusters with the metabolic syndrome and may identify subjects at increased coronary risk. Statin treatment may reduce the incidence of major adverse cardiac events in subjects with the metabolic syndrome, but evidence is limited. We evaluated the impact of pravastatin treatment on the incidence of major adverse cardiac events in microalbuminuric subjects with the metabolic syndrome.

Methods and results This substudy of the PREVEND Intervention Trial (a randomized, placebo-controlled trial with a 2x2 factorial design) included 864 microalbuminuric subjects, who were randomized to fosinopril 20 mg or matching placebo and pravastatin 40 mg or matching placebo (mean follow-up 46 months). The metabolic syndrome was defined according to the NCEP ATPIII-report. Subjects with or without the metabolic syndrome were characterized by a higher age, male sex, and increased albuminuria. The incidence of major adverse cardiac events in subjects with the metabolic syndrome [9.1%; 95% confidence interval (CI) 6.0-13.0%] was increased vs. those without [3.6%; 95% CI 2.3-5.5%; P=0.007). Pravastatin treatment lowered the incidence of major adverse cardiac events in subjects with the metabolic syndrome after adjustment for age and sex (hazard ratio=0.39; 95% CI 0.17-0.89; P=0.025).

Conclusion This study supports the use of statins in microalbuminuric subjects with the metabolic syndrome to reduce the incidence of major adverse cardiac events.

Keywords: PREVEND; Microalbuminuria; Metabolic syndrome; Clinical trial; Statin.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 NEJMHome page
B. C. Fellstrom, A. G. Jardine, R. E. Schmieder, H. Holdaas, K. Bannister, J. Beutler, D.-W. Chae, A. Chevaile, S. M. Cobbe, C. Gronhagen-Riska, et al.
Rosuvastatin and Cardiovascular Events in Patients Undergoing Hemodialysis
N. Engl. J. Med., April 2, 2009; 360(14): 1395 - 1407.
[Abstract] [Full Text] [PDF]

Home page
 Mayo Clin Proc.Home page
J. Danziger
Importance of Low-Grade Albuminuria
Mayo Clin. Proc., July 1, 2008; 83(7): 806 - 812.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
X. J, L. G, W. P, V. H, Y. X, L. Y, W. Y, P. A, C. S, D. GV, et al.
Kidney and Blood Pressure--The Story Unfolds: Renalase Is a Novel, Soluble Monoamine Oxidase That Regulates Cardiac Function and Blood Pressure. J Clin Invest
J. Am. Soc. Nephrol., September 1, 2005; 16(9): 2521 - 2527.
[Full Text] [PDF]

Home page
 Eur Heart JHome page
N. Sattar and N. G. Forouhi
Metabolic syndrome criteria: ready for clinical prime time or work in progress?
Eur. Heart J., July 1, 2005; 26(13): 1249 - 1251.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.